Physician profile
Shuvendu Sen
NPI 1780860684
$226.40
in general payments reported to CMS, 2019-2025
12 companies · $57.36 in 2025
The $57.36 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.38 · 2021: $13.74 · 2022: $15.00 · 2023: $48.51 · 2024: $78.41 · 2025: $57.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $184.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32.94 | 2024 | Wegovy |
| Pfizer INC. | $32.00 | 2022-2023 | |
| Exact Sciences Corporation | $21.10 | 2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $18.89 | 2025 | Heplisav-B |
| Shionogi INC | $17.60 | 2023 | Fetroja |
| Sanofi-Aventis U.S. LLC | $17.37 | 2025 | |
| Abbott Laboratories | $17.11 | 2024 | Octrode |
| Amgen INC. | $14.45 | 2024 | Krystexxa |
| Medtronic, INC. | $13.91 | 2024 | Closurefast |
| Lilly USA, LLC | $13.91 | 2023 | Jardiance |
| Mannkind Corporation | $13.74 | 2021 | |
| Melinta Therapeutics, LLC | $13.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuvendu Sen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.